Merck Wins FDA Approval for First Oral PCSK9 Cholesterol Drug

Merck (NYSE:MRK) has received FDA approval for Lipfendra (enlicitide), the first oral PCSK9 cholesterol-lowering drug. Lipfendra introduces an oral option for patients who have so far relied on injectable PCSK9 therapies. The approval expands Merck's presence in cardiovascular medicine as key products approach patent expirations.

The Product

Lipfendra (enlicitide) is the first oral PCSK9 inhibitor, a class of drugs that significantly lowers LDL cholesterol. Unlike current injectable therapies (e.g., Repatha and Praluent), Lipfendra can be taken orally, potentially improving patient adherence.

Pricing and Availability

Merck has not yet announced the price or commercial launch date for Lipfendra. The company is expected to set pricing based on efficacy compared to existing injectable treatments.

Competition

Lipfendra faces competition from injectable PCSK9 inhibitors such as Repatha (Amgen) and Praluent (Sanofi/Regeneron), as well as other cholesterol drugs like statins. Being the first oral option may provide a competitive edge.

Potential Impact on the Company

Lipfendra is expected to boost Merck's cardiovascular revenue, especially as patents for key drugs like Keytruda approach expiration. However, commercial success depends on pricing and adoption by physicians and patients. Merck (MRK) has posted a 64.8% return over the past year and 92.2% over five years.